Management strategies in rheumatoid arthritis.

Journal

Nature reviews. Rheumatology

ISSN: 1759-4804

Titre abrégé: Nat Rev Rheumatol

Pays: United States

ID NLM: 101500080

Informations de publication

Date de publication:
24 Oct 2024

Historique:

accepted: 04 09 2024

medline: 25 10 2024

pubmed: 25 10 2024

entrez: 25 10 2024

Statut: aheadofprint

Résumé

Management of rheumatoid arthritis (RA) has evolved from simply the direct translation of drug efficacy results from clinical trials to patient care, to a more complex longitudinal process that considers not only drug efficacy but also the safety gestalt of a treatment and patient profiles and preferences, as well as health-economic factors. With numerous DMARDs available to treat RA, knowledge about trial efficacy becomes less important than data that inform an appropriate clinical strategy for their optimal selection and use. Overly ambitious approaches targeting the 'maximum' level of success could, for example, be prone to failure and create frustration, and lead to a large number of patients then being considered as 'difficult to treat'. Safety profiles might be more informative than efficacy profiles for precision medicine approaches. Contemporary RA management strategies might therefore take a more holistic approach, beyond merely efficacy, to the setting of targets that lead to improved compliance rather than aspirational successes, with consideration of each patient's multimorbidity profile and preferences, as well as the safety profile of each treatment. Ultimately, the goal remains unchanged: maximizing health-related quality of life; however, with a focus on optimal balance rather than superlatives.

Identifiants

DOI: 10.1038/s41584-024-01169-7 PMID: 39448800

pubmed: 39448800

doi: 10.1038/s41584-024-01169-7

pii: 10.1038/s41584-024-01169-7

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Bluhm, G. B. The treatment of rheumatoid arthritis with gold. Semin. Arthritis Rheum. 5, 147–166 (1975).

pubmed: 810893 doi: 10.1016/0049-0172(75)90003-7

Bunch, T. W. & O’Duffy, J. D. Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin. Proc. 55, 161–179 (1980).

pubmed: 6766523

Lee, D. M. & Weinblatt, M. E. Rheumatoid arthritis. Lancet 358, 903–911 (2001).

pubmed: 11567728 doi: 10.1016/S0140-6736(01)06075-5

Hoes, J. N., Jacobs, J. W. G., Buttgereit, F. & Bijlsma, J. W. J. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat. Rev. Rheumatol. 6, 693–702 (2010).

pubmed: 21119718 doi: 10.1038/nrrheum.2010.179

Doumen, M., Pazmino, S., Bertrand, D., Westhovens, R. & Verschueren, P. Glucocorticoids in rheumatoid arthritis: balancing benefits and harm by leveraging the therapeutic window of opportunity. Joint Bone Spine 90, 105491 (2023).

pubmed: 36410680 doi: 10.1016/j.jbspin.2022.105491

Weinstein, G. D. Methotrexate. Ann. Intern. Med. 86, 199–204 (1977).

pubmed: 319725 doi: 10.7326/0003-4819-86-2-199

Tugwell, P., Bennett, K. & Gent, M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, safety. Ann. Intern. Med. 107, 358–366 (1987).

pubmed: 3304050 doi: 10.7326/0003-4819-107-2-358

Weinblatt, M. E. & Kremer, J. M. Methotrexate in rheumatoid arthritis. J. Am. Acad. Dermatol. 19, 126–128 (1988).

pubmed: 3042815 doi: 10.1016/S0190-9622(88)80220-2

Fries, J. F., Williams, C. A., Ramey, D. & Bloch, D. A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum. 36, 297–306 (1993).

pubmed: 8452574 doi: 10.1002/art.1780360303

Shergy, W. J. et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am. J. Med. 85, 771–774 (1988).

pubmed: 3195601 doi: 10.1016/S0002-9343(88)80019-6

Smyth, C. J. Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad. Med. 51, 31–39 (1972).

pubmed: 4555072 doi: 10.1080/00325481.1972.11698261

Fries, J. F. Safety issues related to DMARD therapy. J. Rheumatol. Suppl. 25, 14–17 (1990).

pubmed: 2273518

Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360–1372 (2018).

pubmed: 30285183 doi: 10.1001/jama.2018.13103

Aletaha, D. et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann. Rheum. Dis. 67, 1360–1364 (2008).

pubmed: 18791055 doi: 10.1136/ard.2008.091454

Felson, D. T. et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404–413 (2011).

pubmed: 21292833 doi: 10.1136/ard.2011.149765

Østergaard, M. et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann. Rheum. Dis. 82, 1286–1295 (2023).

pubmed: 37423647 doi: 10.1136/ard-2023-224116

Verschueren, P. et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann. Rheum. Dis. 76, 511–520 (2017).

pubmed: 27432356 doi: 10.1136/annrheumdis-2016-209212

Gottenberg, J.-E. et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316, 1172–1180 (2016).

pubmed: 27654603 doi: 10.1001/jama.2016.13512

Porter, D. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388, 239–247 (2016).

pubmed: 27197690 doi: 10.1016/S0140-6736(16)00380-9

Sokka, T. & Pincus, T. Rheumatoid arthritis: strategy more important than agent. Lancet 374, 430–432 (2009).

pubmed: 19665630 doi: 10.1016/S0140-6736(09)61432-X

Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3–15 (2016).

pubmed: 25969430 doi: 10.1136/annrheumdis-2015-207524

Smolen, J. S. & Aletaha, D. Forget personalised medicine and focus on abating disease activity. Ann. Rheum. Dis. 72, 3–6 (2013).

pubmed: 23136241 doi: 10.1136/annrheumdis-2012-202361

Pincus, T., Gibson, K. A. & Castrejón, I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull. Hosp. Jt Dis. 71, S9–S19 (2013).

Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019–2033 (2023).

pubmed: 38240831 doi: 10.1016/S0140-6736(23)01525-8

Takeuchi, T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin. Immunol. 186, 59–62 (2018).

pubmed: 28736274 doi: 10.1016/j.clim.2017.07.019

Aletaha, D. Precision medicine and management of rheumatoid arthritis. J. Autoimmun. 110, 102405 (2020).

pubmed: 32276742 doi: 10.1016/j.jaut.2020.102405

Wientjes, M. H. M., den Broeder, A. A., Welsing, P. M. J., Verhoef, L. M. & van den Bemt, B. J. F. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review. RMD Open 8, e002570 (2022).

pubmed: 36597975 pmcid: 9730399 doi: 10.1136/rmdopen-2022-002570

Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305–317 (2021).

pubmed: 33485455 pmcid: 7829614 doi: 10.1016/S0140-6736(20)32341-2

Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).

pubmed: 35589854 pmcid: 9205785 doi: 10.1038/s41591-022-01789-0

Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338–2348 (2017).

pubmed: 28612748 doi: 10.1016/S0140-6736(17)31491-5

Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995).

pubmed: 7779114 doi: 10.1002/art.1780380602

Konzett, V., Kerschbaumer, A., Smolen, J. S. & Aletaha, D. Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis. Ann. Rheum. Dis. 83, 58–64 (2024).

pubmed: 37758287 doi: 10.1136/ard-2023-224477

Smolen, J. S. & Aletaha, D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat. Rev. Rheumatol. 11, 276–289 (2015).

pubmed: 25687177 doi: 10.1038/nrrheum.2015.8

Lin, C. M. A., Cooles, F. A. H. & Isaacs, J. D. Precision medicine: the precision gap in rheumatic disease. Nat. Rev. Rheumatol. 18, 725–733 (2022).

pubmed: 36216923 doi: 10.1038/s41584-022-00845-w

Dey, M., Nagy, G. & Nikiphorou, E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology 62, 1773–1779 (2023).

pubmed: 36205537 doi: 10.1093/rheumatology/keac584

Finckh, A. et al. Global epidemiology of rheumatoid arthritis. Nat. Rev. Rheumatol. 18, 591–602 (2022).

pubmed: 36068354

Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038 (2016).

pubmed: 27156434 doi: 10.1016/S0140-6736(16)30173-8

Radner, H. et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology 54, 2076–2084 (2015).

pubmed: 26163688 doi: 10.1093/rheumatology/kev239

Dey, M., Nagy, G. & Nikiphorou, E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology 61, 3881–3883 (2022).

pubmed: 35244149 doi: 10.1093/rheumatology/keac134

Baillet, A. et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann. Rheum. Dis. 75, 965–973 (2016).

pubmed: 26984008 doi: 10.1136/annrheumdis-2016-209233

Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).

pubmed: 27697765 doi: 10.1136/annrheumdis-2016-209775

Sandberg, M. E. C. et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann. Rheum. Dis. 73, 2029–2033 (2014).

pubmed: 24818635 doi: 10.1136/annrheumdis-2013-205094

Roodenrijs, N. M. T. et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology 60, 5105–5116 (2021).

pubmed: 33560301 doi: 10.1093/rheumatology/keab130

Battafarano, D. F. et al. 2015 American College of Rheumatology Workforce Study: supply and demand projections of adult rheumatology workforce, 2015-2030. Arthritis Care Res. 70, 617–626 (2018).

doi: 10.1002/acr.23518

Kilian, A., Upton, L. A., Battafarano, D. F. & Monrad, S. U. Workforce trends in rheumatology. Rheum. Dis. Clin. North. Am. 45, 13–26 (2019).

pubmed: 30447742 doi: 10.1016/j.rdc.2018.09.002

Tournadre, A., Pereira, B., Gossec, L., Soubrier, M. & Dougados, M. Impact of comorbidities on fatigue in rheumatoid arthritis patients: results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine 86, 55–60 (2019).

pubmed: 30025953 doi: 10.1016/j.jbspin.2018.06.010

Katz, J. & Bartels, C. M. Multimorbidity in rheumatoid arthritis: literature review and future directions. Curr. Rheumatol. Rep. 26, 24–35 (2024).

pubmed: 37995046 doi: 10.1007/s11926-023-01121-w

Gossec, L. et al. Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. RMD Open 5, e000914 (2019).

pubmed: 31275607 pmcid: 6579559 doi: 10.1136/rmdopen-2019-000914

Singh, J. A. et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386, 258–265 (2015).

pubmed: 25975452 pmcid: 4580232 doi: 10.1016/S0140-6736(14)61704-9

Sepriano, A. et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 82, 107–118 (2023).

pubmed: 36376026 doi: 10.1136/ard-2022-223357

Di Martino, V. et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat. Rev. Rheumatol. 19, 96–110 (2023).

pubmed: 36564450 doi: 10.1038/s41584-022-00883-4

Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).

pubmed: 12796126 doi: 10.1161/01.CIR.0000077913.60364.D2

Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594–1502 (2004).

pubmed: 15023878 doi: 10.1161/01.CIR.0000124490.27666.B2

Do, T. T. H. et al. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration. J. Steroid Biochem. Mol. Biol. 185, 150–162 (2019).

pubmed: 30145227 doi: 10.1016/j.jsbmb.2018.08.010

Curtis, B. R. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am. Soc. Hematol. Educ. Program 2017, 187–193 (2017).

pubmed: 29222255 pmcid: 6142577 doi: 10.1182/asheducation-2017.1.187

de Germay, S., Bagheri, H., Despas, F., Rousseau, V. & Montastruc, F. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology 59, 2360–2367 (2020).

pubmed: 31880308 doi: 10.1093/rheumatology/kez604

Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).

pubmed: 35081280 doi: 10.1056/NEJMoa2109927

Seror, R. et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology 52, 868–874 (2013).

pubmed: 23287362 doi: 10.1093/rheumatology/kes375

Fraenel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73, 1108–1123 (2021).

doi: 10.1002/art.41752

Narváez, J. et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment. Reumatol. Clin. 18, 501–512 (2022).

pubmed: 36064885 doi: 10.1016/j.reuma.2022.03.005

Yu, K.-H. et al. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine 101, e28501 (2022).

pubmed: 35029907 pmcid: 8735742 doi: 10.1097/MD.0000000000028501

Salaffi, F., Di Carlo, M., Farah, S. & Carotti, M. Adherence to subcutaneous anti-TNFα agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site. Int. J. Rheum. Dis. 23, 480–487 (2020).

pubmed: 32124567 doi: 10.1111/1756-185X.13803

Hsieh, P.-H. et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann. Rheum. Dis. 79, 771–777 (2020).

pubmed: 32245893 doi: 10.1136/annrheumdis-2019-216243

Smolen, J. S. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244–257 (2003).

pubmed: 12595618 doi: 10.1093/rheumatology/keg072

Aletaha, D. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res. Ther. 7, R796–R806 (2005).

pubmed: 15987481 pmcid: 1175030 doi: 10.1186/ar1740

van der Heijde, D. M., Van ’t Hof, M., van Riel, P. L. & van de Putte, L. B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20, 579–581 (1993).

pubmed: 8478878

Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48 (1995).

pubmed: 7818570 doi: 10.1002/art.1780380107

Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004).

pubmed: 15262104 doi: 10.1016/S0140-6736(04)16676-2

Kavanaugh, A. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72, 64–71 (2013).

pubmed: 22562973 doi: 10.1136/annrheumdis-2011-201247

Keystone, E. C., Kavanaugh, A., Weinblatt, M. E., Patra, K. & Pangan, A. L. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J. Rheumatol. 38, 855–862 (2011).

pubmed: 21285171 doi: 10.3899/jrheum.100752

Klarenbeek, N. B. et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1815–1821 (2011).

pubmed: 21813548 doi: 10.1136/ard.2010.149260

Schipper, L. G. et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology 49, 2154–2164 (2010).

pubmed: 20671022 doi: 10.1093/rheumatology/keq195

Aletaha, D. et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 60, 1242–1249 (2009).

pubmed: 19404938 doi: 10.1002/art.24433

van Leeuwen, M. A. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21, 425–429 (1994).

pubmed: 7516430

Gul, H. L., Ferreira, J. F. & Emery, P. Remission in rheumatoid arthritis: is it all the same? Expert. Rev. Clin. Pharmacol. 8, 575–586 (2015).

pubmed: 26131966 doi: 10.1586/17512433.2015.1061429

Mankia, K., Gul, H. & Emery, P. Treating rheumatoid arthritis to an imaging target produces better outcomes, or does it? Rheumatology 60, 3–4 (2021).

pubmed: 33175981 doi: 10.1093/rheumatology/keaa659

Haavardsholm, E. A. et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354, i4205 (2016).

pubmed: 27530741 pmcid: 4986519 doi: 10.1136/bmj.i4205

Dale, J. et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann. Rheum. Dis. 75, 1043–1050 (2016).

pubmed: 27026689 doi: 10.1136/annrheumdis-2015-208941

Møller-Bisgaard, S. et al. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE-RA randomized clinical trial. JAMA 321, 461–472 (2019).

pubmed: 30721294 pmcid: 6440221 doi: 10.1001/jama.2018.21362

Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631–637 (2010).

pubmed: 20215140 doi: 10.1136/ard.2009.123919

Buch, M. H. Defining refractory rheumatoid arthritis. Ann. Rheum. Dis. 77, 966–969 (2018).

pubmed: 29588276 doi: 10.1136/annrheumdis-2017-212862

Gossec, L., Dougados, M. & Dixon, W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 1, e000019 (2015).

pubmed: 26509052 pmcid: 4613162 doi: 10.1136/rmdopen-2014-000019

Studenic, P. et al. Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? Ann. Rheum. Dis. 79, 445–452 (2020).

pubmed: 32024651 doi: 10.1136/annrheumdis-2019-216529

Studenic, P. et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann. Rheum. Dis. 82, 74–80 (2023).

pubmed: 36280238 doi: 10.1136/ard-2022-223413

Studenic, P., Radner, H., Smolen, J. S. & Aletaha, D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 64, 2814–2823 (2012).

pubmed: 22810704 doi: 10.1002/art.34543

Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68, 823–827 (2009).

pubmed: 18593759 doi: 10.1136/ard.2008.090019

Smolen, J. S. et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52, 1020–1030 (2005).

pubmed: 15818697 doi: 10.1002/art.20982

Landewé, R., van der Heijde, D., Klareskog, L., van Vollenhoven, R. & Fatenejad, S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 54, 3119–3125 (2006).

pubmed: 17009230 doi: 10.1002/art.22143

Smolen, J. S., Avila, J. C. M. & Aletaha, D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann. Rheum. Dis. 71, 687–693 (2012).

pubmed: 22121130 doi: 10.1136/annrheumdis-2011-200395

Aletaha, D., Alasti, F. & Smolen, J. S. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann. Rheum. Dis. 72, 7–12 (2013).

pubmed: 22915619 doi: 10.1136/annrheumdis-2012-201970

Lopez-Romero, P., de la Torre, I., Haladyj, E., Aletaha, D. & Smolen, J. S. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Ann. Rheum. Dis. 81, 622–631 (2022).

pubmed: 35193872 doi: 10.1136/annrheumdis-2021-221323

Binder, N. B. et al. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum. 65, 608–617 (2013).

pubmed: 23280418 doi: 10.1002/art.37797

Listing, J. et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res. Ther. 8, R66 (2006).

pubmed: 16600016 pmcid: 1526636 doi: 10.1186/ar1933

Gaujoux-Viala, C. et al. Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System. RMD Open 9, e003075 (2023).

pubmed: 37914177 pmcid: 10619049 doi: 10.1136/rmdopen-2023-003075

Olsen, I. C. et al. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology 58, 481–491 (2019).

pubmed: 30508189 doi: 10.1093/rheumatology/key338

Brinkmann, G. H. et al. Treat to target strategy in early rheumatoid arthritis versus routine care – a comparative clinical practice study. Semin. Arthritis Rheum. 48, 808–814 (2019).

pubmed: 30205983 doi: 10.1016/j.semarthrit.2018.07.004

Gärtner, M. et al. Persistence of subclinical sonographic joint activity in rheumatoid arthritis in sustained clinical remission. Ann. Rheum. Dis. 74, 2050–2053 (2015).

pubmed: 25977561 doi: 10.1136/annrheumdis-2014-207212

Pareto, V. Cours d’Économie Politique Nouvelle édition par Bousquet, G.-H. et Busino, G. 313–315 (Droz, 1964).

Goekoop-Ruiterman, Y. P. M. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 58, S126–S135 (2008).

pubmed: 18240203 doi: 10.1002/art.23364

Heimans, L. et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann. Rheum. Dis. 73, 1356–1361 (2014).

pubmed: 23716067 doi: 10.1136/annrheumdis-2013-203243

Bathon, J. M. & Genovese, M. C. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin. Exp. Rheumatol. 21, S195–S197 (2003).

pubmed: 14969076

Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377–2386 (2014).

pubmed: 24941177 doi: 10.1056/NEJMoa1310476

Roodenrijs, N. M. T. et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 7, e001512 (2021).

pubmed: 33419871 pmcid: 7798678 doi: 10.1136/rmdopen-2020-001512

Busby, A. D. et al. The role of comorbidities alongside patient and disease characteristics in long-term disease activity in RA using UK inception cohort data. Rheumatology 61, 4297–4304 (2022).

pubmed: 35258566 pmcid: 9629371 doi: 10.1093/rheumatology/keac139

Bertsias, A. et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with “difficult to treat” rheumatoid arthritis. RMD Open 10, e003808 (2024).

pubmed: 38242549 pmcid: 10806522 doi: 10.1136/rmdopen-2023-003808

Kjørholt, K. E. et al. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. Lancet Rheumatol. 6, e268–e278 (2024).

pubmed: 38583450 doi: 10.1016/S2665-9913(24)00021-3

Tascilar, K. et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 3, e767–e777 (2021).

pubmed: 38297524 doi: 10.1016/S2665-9913(21)00220-4

Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3–18 (2023).

pubmed: 36357155 doi: 10.1136/ard-2022-223356

Gerriets, V., Goyal, A. & Khaddour, K. Tumor necrosis factor inhibitors (StatPearls, 2024).

Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909–920 (2011).

pubmed: 21378402 doi: 10.1136/ard.2010.144998

Burmester, G. R. et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9, e002735 (2023).

pubmed: 36754548 pmcid: 9923346 doi: 10.1136/rmdopen-2022-002735

Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 13, 234–243 (2017).

pubmed: 28250461 doi: 10.1038/nrrheum.2017.23

Montastruc, F. et al. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology 58, 683–691 (2019).

pubmed: 30535094 doi: 10.1093/rheumatology/key352

Simon, T. A. et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res. Ther. 21, 228 (2019).

pubmed: 31703717 pmcid: 6839238 doi: 10.1186/s13075-019-1992-x

Kastrati, K. et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8, e002359 (2022).

pubmed: 36260501 pmcid: 9462104 doi: 10.1136/rmdopen-2022-002359

Rempenault, C. et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology 61, 953–962 (2022).

pubmed: 33993216 doi: 10.1093/rheumatology/keab438

Smolen, J. S. et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J. Rheumatol. 46, 7–18 (2019).

pubmed: 30219772 doi: 10.3899/jrheum.171361

Hoisnard, L. et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep. 12, 7140 (2022).

pubmed: 35504889 pmcid: 9065106 doi: 10.1038/s41598-022-10777-w

Aringer, M. & Smolen, J. S. TNF inhibition in SLE: where do we stand? Lupus 18, 5–8 (2009).

pubmed: 19074162 doi: 10.1177/0961203308098190

Charles, P. J., Smeenk, R. J., De Jong, J., Feldmann, M. & Maini, R. N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43, 2383–2390 (2000).

pubmed: 11083258 doi: 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D

Kaltsonoudis, E., Voulgari, P. V., Konitsiotis, S. & Drosos, A. A. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun. Rev. 13, 54–58 (2014).

pubmed: 24035809 doi: 10.1016/j.autrev.2013.09.002

Winkelmann, A., Patejdl, R., Wagner, S., Benecke, R. & Zettl, U. K. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J. Neurol. 255, 109–114 (2008).

pubmed: 19300970 doi: 10.1007/s00415-008-6020-z

Buch, M. H., Johnsen, A. & Schiff, M. Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. Clin. Exp. Rheumatol. 37, 127–132 (2019).

pubmed: 30148437

Bonelli, M. M., Mrak, D., Perkmann, T., Haslacher, H. & Aletaha, D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann. Rheum. Dis. 80, 1355–1356 (2021).

pubmed: 33958323 doi: 10.1136/annrheumdis-2021-220408

Mrak, D. et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann. Rheum. Dis. 80, 1345–1350 (2021).

pubmed: 34285048 doi: 10.1136/annrheumdis-2021-220781